The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
COVID-19 in kidney transplant recipients
Open accessAbstract
To the Editor: An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that began in Wuhan, China, has spread rapidly and has already taken on pandemic proportions.1Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? [published online ahead of print March 13, 2020]. Lancet. https://doi.org/10.1016/S0140-6736(20)30627-9Google Scholar After China, Italy is the country with the highest number of cases so far (41 035 confirmed cases according to Dipartimento della Protezione Civile as of March 19, and 3405 deaths). In Northern Italy, where the current prevalence of confirmed cases has surpassed in some areas 2 per 1000 people, kidney transplant patients are getting infected and starting to develop coronavirus disease 2019 (COVID-19). There are only limited data on COVID-19 in transplant recipients.2Zhu L, Xu X, Ma KE, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression [published online ahead of print March 17, 2020]. Am J Transplant. https://doi.org/10.1111/AJT.15869Google Scholar Herein, we report the outcomes of two deceased-donor kidney transplant recipients with COVID-19 pneumonia admitted to the Hospital of Parma (Parma, Italy), between March 2 and 12, 2020. One was a 75-year-old male (patient 1) and the other a 52-year-old female (patient 2), at 120 and 8 months after transplant, respectively (Table 1). Symptoms (cough, myalgia, and fever 38-39°C) started 3 and 1 days before admission for patients 1 and 2, respectively. At the time of infection diagnosis, graft function was stable in patient 1, while patient 2 had developed acute kidney injury (AKI). Both patients were on tacrolimus (Tac), steroids, and mycophenolate mofetil. Both patients presented with fever (38-39°C) and dyspnea at admission. Lung CT scan at admission showed typical radiological findings of COVID-19 pneumonia, with extensive bilateral ground-glass opacities in both; specific treatment was started before arrival of nasopharyngeal swab test results (PCR, confirming SARS-CoV-2 infection on day 3 and 2 after symptoms’ onset). Mycophenolate and Tac were discontinued on the day of admission and both patients received hydroxychloroquine (200 mg twice daily) in addition to lopinavir + ritonavir or darunavir + cobicistat. None of the patients were on ACE inhibitors or ARBs. Both patients required non-invasive ventilation, but no patient was transferred to the ICU. Patient 1 developed abrupt worsening of his respiratory conditions over a period of 24 to 38 hours and expired 5 days after admission before intubation. On day 6 after admission, patient 2 showed signs of systemic inflammation (plasmatic IL-6:108.2 pg/mL; normal range 0-10 pg/mL; Table 1). After progressive worsening of respiratory conditions requiring non-invasive ventilation and being considered for intubation, the patient received colchicine (1 mg on day 8, and 0.5 mg/day thereafter) to reduce inflammation, due the unavailability of anti-IL-6 receptor mAb tocilizumab. Anti-retroviral therapy was stopped; 24 hour after colchicine administration, plasmatic IL-6 concentration decreased to 36 pg/mL, and respiratory conditions stabilized. At the time of writing (day 14 after initial symptoms), the patient is alert and stable on non-invasive ventilation positive airway pressure (PaO2/FiO2 114, respiratory rate 22 rpm, arterial blood pressure 150/90 mm Hg, hear rate 105 rpm). Serum creatinine has returned to baseline levels (1.4 mg/dL) and liver function test are normal. Tacrolimus blood trough levels had initially increased to 39.9 μg/L due to interaction with ritonavir and transient liver failure despite holding tacrolimus. On follow-up, Tac trough levels had returned to target range and Tac was resumed on day 12 (blood levels 5.4 µg/L on Tac 0.5 mg twice daily).TABLE 1Patient characteristics at admissionPatients12VariablesSexMFAge (y)7552RaceWhiteWhiteMonths post-Tx1208DonorsDeceasedDeceased (DCD)HistoryPrimary nephropathyPyelonephritisUnknownFlu vaccinationYesYesLung diseaseCOPDNoHeart diseaseYesNoHypertensionYesYesCancerNoNoObesityYesNoVital signsRespiratory rate (rpm)2528Heart rate (rpm)10193Blood pressure (mm Hg)140/70130/70PO2/fiO2276247Signs/symptomsFever (T > 37.5°C)YesYesDyspneaYesYesDiarrheaNoYesMyalgiasYesYesAKINoYesCT (% of lung involvement)40%50%Positive swab testYesYesBiochemistrys-Creat (mg/dL); d0, d3, d7 (baseline creatinine)2.2; 2.2; NA (2.1)2.4; 3.4; 2.9 (1.3)PTL (×103/mmc)164386WBC (×103/mmc)6.562.54Lymphocytes (cells/mmc) d0, d3, d7880; 650; NA110; 120; 50Hb (g/dL)11.711.6d-dim (ng/mL)NA832AST(IU/mL)4562ALT (IU/mL)2526LDH (IU/mL)301718CPK (IU/mL)82197CRP (mg/L); d0, d3, d7180; >20; NA158; 100; 43Procalcitonin (ng/mL)1.290.98Concurrent/previous relevant therapyInduction therapyThymoThymoMaintenance immunosuppressionTac, MMF, StTac, MMF, StACEiNoNoARBNoNoImmunosuppression withdrawalTacYesYesMMFYesYesSteroidsNoNoAntiviral/antibioticsAntibioticsYesYesHydroxychloroquineYesYesLopinavir/rit
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COVID-19 and Italy: what next?
Remuzzi, A., & Remuzzi, G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30627-9 · Cited by 3,119
Cited by
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
COVID-19 in solid organ transplant recipients: A single-center case series from Spain
Fernández-Ruiz, M., Andrés, A., Loinaz, C., Delgado, J. F., López-Medrano, F., San Juan, R., González, E., Polanco, N., Folgueira, M. D., Lalueza, A., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15929 · Cited by 392
Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations
Thakur, V., Ratho, R. K., Kumar, P., Bhatia, S. K., Bora, I., Mohi, G. K., Saxena, S. K., Devi, M., Yadav, D., & Mehariya, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030446 · Cited by 147
Metadata
- Authors
- Gandolfini, I., Delsante, M., Fiaccadori, E., Zaza, G., Manenti, L., Degli Antoni, A., Peruzzi, L., Riella, L. V., Cravedi, P., & Maggiore, U.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 20
- Issue
- 7
- Pages
- 1941-1943
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W3013598589
- Cited by
- 211
- References
- 1
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 in kidney transplant recipients. https://app.cochat.ai/papers/10.1111/ajt.15891
- The paper
- Gandolfini, I., Delsante, M., Fiaccadori, E., Zaza, G., Manenti, L., Degli Antoni, A., Peruzzi, L., Riella, L. V., Cravedi, P., & Maggiore, U. (2020). COVID-19 in kidney transplant recipients. American Journal of Transplantation. https://doi.org/10.1111/ajt.15891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.